Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis

Zhang,Xi; Xu,Xinchen; Liu,Xuqiang; Mao,Chuanyuan; Qin,An; Lu,Eryi

doi:10.3892/mmr.2017.8223

Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis

Authors:
- Xi Zhang
- Xinchen Xu
- Xuqiang Liu
- Chuanyuan Mao
- An Qin
- Eryi Lu
View Affiliations

Affiliations: Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Nanchang University, The Artificial Joint Engineering and Technology Research Center of Jiangxi Province, Nanchang, Jiangxi 330200, P.R. China, Department of Orthopedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Orthopedic Implants, Shanghai 200011, P.R. China
Published online on: December 8, 2017 https://doi.org/10.3892/mmr.2017.8223
Pages: 3232-3238

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen‑deficiency. Bone loss associated with bisphosphonates therapy can increase the risk of developing oral osteonecrosis. Recent studies have indicated that enoxacin may inhibit osteoclast formation and bone resorption via a different mechanism from that of bisphosphonates. Therefore, the authors hypothesized that the use of an enoxacin such as bis‑enoxacin (BE) in association with bisphosphonates may be effective in the treatment of postmenopausal osteoporosis‑associated alveolar bone resorption and reduce the risk of oral osteonecrosis by allowing the dose of bisphosphonates to be reduced. A total of 30 6‑month‑old female Sprague‑Dawley rats were randomly assigned to five groups: The Sham, Vehicle, zoledronic acid (ZOL), low concentrations of BE (BE‑L) and high concentrations of BE (BE‑H) groups. The results demonstrated that the ZOL, BE‑L and BE‑H groups had an increased bone volume/tissue volume, trabecular thickness, mineral apposition rate, mineralizing surface/bone surface and a decreased trabecular separation when compared with the Vehicle group. The microscopic evaluation of histological sections clearly supported the results of the micro‑computed tomography. The number of tartrate‑resistant acid phosphatase‑positive osteoclasts was markedly decreased in the ZOL, BE‑L and BE‑H groups, indicating that BE may inhibit osteoclast formation. The anti‑resorptive effect in the BE‑H group was close to or better than that exhibited by the ZOL group; however, this effect was poorer in the BE‑L group. In conclusion, BE has the potential to block alveolar bone resorption resulting from ovariectomy‑induced osteoporosis in rats in a dose‑dependent manner.

View Figures

View References

1	McGrath C and Bedi R: The importance of oral health to older people's quality of life. Gerodontology. 16:59–63. 1999. View Article : Google Scholar : PubMed/NCBI
2	Howson CP: Perspectives and needs for health in the 21st century: 20th-century paradigms in 21st-century science. J Hum Virol. 3:94–103. 2000.PubMed/NCBI
3	Dempster DW, Birchman R, Xu R, Lindsay R and Shen V: Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone. 16:157–161. 1995. View Article : Google Scholar : PubMed/NCBI
4	Kribbs PJ, Chesnut CH III, Ott SM and Kilcoyne RF: Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent. 62:703–707. 1989. View Article : Google Scholar : PubMed/NCBI
5	Kribbs PJ: Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent. 63:218–222. 1990. View Article : Google Scholar : PubMed/NCBI
6	Jeffcoat MK: Osteoporosis: A possible modifying factor in oral bone loss. Ann Periodontol. 3:312–321. 1998. View Article : Google Scholar : PubMed/NCBI
7	Purdue PE, Koulouvaris P, Potter HG, Nestor BJ and Sculco TP: The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res. 454:251–261. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sun W, Wang YQ, Yan Q, Lu R and Shi B: Effects of Er-Zhi-Wan on microarchitecture and regulation of Wnt/β-catenin signaling pathway in alveolar bone of ovariectomized rats. J Huazhong Univ Sci Technolog Med Sci. 34:114–119. 2014. View Article : Google Scholar : PubMed/NCBI
9	Black DM and Rosen CJ: Postmenopausal osteoporosis. N Engl J Med. 374:254–262. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, et al: Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA. 290:1729–1738. 2003. View Article : Google Scholar : PubMed/NCBI
11	Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R and Kerlikowske K: Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk. J Natl Cancer Inst. 101:384–398. 2009. View Article : Google Scholar : PubMed/NCBI
12	Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A and Shekelle PG: Comparative effectiveness of pharmacologic treatments to prevent fractures: An updated systematic review. Ann Intern Med. 161:711–723. 2014. View Article : Google Scholar : PubMed/NCBI
13	Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D and Potts JT: Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 97:2272–2282. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, et al: Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 29:1–23. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tella SH and Gallagher JC: Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 142:155–170. 2014. View Article : Google Scholar : PubMed/NCBI
16	Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA and Rosen CJ: PaTH Study Investigators: One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 353:555–565. 2005. View Article : Google Scholar : PubMed/NCBI
17	Ostrov DA, Magis AT, Wronski TJ, Chan EK, Toro EJ, Donatelli RE, Sajek K, Haroun IN, Nagib MI, Piedrahita A, et al: Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem. 52:5144–5151. 2009. View Article : Google Scholar : PubMed/NCBI
18	Herczegh P, Buxton TB, McPherson JC III, Kovács-Kulyassa A, Brewer PD, Sztaricskai F, Stroebel GG, Plowman KM, Farcasiu D and Hartmann JF: Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials. J Med Chem. 45:2338–2341. 2002. View Article : Google Scholar : PubMed/NCBI
19	Thompson DD, Simmons HA, Pirie CM and Ke HZ: FDA Guidelines and animal models for osteoporosis. Bone. 17 4 Suppl:125S–133S. 1995. View Article : Google Scholar : PubMed/NCBI
20	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 843:1–129. 1994.PubMed/NCBI
21	Tuck SP and Francis RM: Osteoporosis. Postgrad Med J. 78:526–532. 2002. View Article : Google Scholar : PubMed/NCBI
22	Yang J, Pham SM and Crabbe DL: Effects of oestrogen deficiency on rat mandibular and tibial microarchitecture. Dentomaxillofac Radiol. 32:247–251. 2003. View Article : Google Scholar : PubMed/NCBI
23	Mavropoulos A, Rizzoli R and Ammann P: Different responsiveness of alveolar and tibial bone to bone loss stimuli. J Bone Miner Res. 22:403–410. 2007. View Article : Google Scholar : PubMed/NCBI
24	Dai QG, Zhang P, Wu YQ, Ma XH, Pang J, Jiang LY and Fang B: Ovariectomy induces osteoporosis in the maxillary alveolar bone: An in vivo micro-CT and histomorphometric analysis in rats. Oral Dis. 20:514–520. 2014. View Article : Google Scholar : PubMed/NCBI
25	Al Habashneh R, Azar W, Shaweesh A and Khader Y: The relationship between body mass index and periodontitis among postmenopausal women. Obes Res Clin Pract. 10:15–23. 2016. View Article : Google Scholar : PubMed/NCBI
26	Salazar M, Hernandes L, Ramos AL, Salazar Bde O, Micheletti KR, Paranhos LR, de Mendonça MR and Cuoghi OA: Effect of alendronate sodium on tooth movement in ovariectomized rats. Arch Oral Biol. 60:776–781. 2015. View Article : Google Scholar : PubMed/NCBI
27	von Wowern N: General and oral aspects of osteoporosis: A review. Clin Oral Investig. 5:71–82. 2001. View Article : Google Scholar : PubMed/NCBI
28	Chen H, Xu X, Liu M, Zhang W, Ke HZ, Qin A, Tang T and Lu E: Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 76:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H, Ouyang Z, Xu X, Wang W, Fan Q, et al: The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 35:5721–5730. 2014. View Article : Google Scholar : PubMed/NCBI
30	Toro EJ, Zuo J, Gutierrez A, La Rosa RL, Gawron AJ, Bradaschia-Correa V, Arana-Chavez V, Dolce C, Rivera MF, Kesavalu L, et al: Bis-enoxacin inhibits bone resorption and orthodontic tooth movement. J Dent Res. 92:925–931. 2013. View Article : Google Scholar : PubMed/NCBI
31	Rivera MF, Chukkapalli SS, Velsko IM, Lee JY, Bhattacharyya I, Dolce C, Toro EJ, Holliday LS and Kesavalu L: Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis. PLoS One. 9:e921192014. View Article : Google Scholar : PubMed/NCBI